Pulse Biosciences stock stays tied to filings and financing
Pulse Biosciences (PLSE) stock continues to be influenced by its Nasdaq listing, corporate disclosures, and clinical development work rather than commercial scale. As a life-sciences developer, investor focus remains on regulatory progress, financing, and program timing, with special attention to how its bioelectric medicine programs advance without excessive dilution. The company's filings and investor materials are crucial for tracking its capital needs and development updates.
Did Warrant Redemptions Just Reframe Pulse Biosciences' (PLSE) Cardiac Ablation Investment Narrative?
Pulse Biosciences recently announced the redemption of remaining common stock warrants from its July 2024 rights offering, a move that could affect its capital structure and long-term positioning in cardiac ablation. This decision, alongside fresh analyst coverage and insider share purchases, focuses on how the company plans to fund its NANOPULSE AF pivotal study and broader nsPFA rollout. While warrant redemption reduces uncertainty around future share issuance, investors should consider the continuous need for cash against its current losses and limited sales.
Price to earnings forward of Pulse Biosciences, Inc – NASDAQ:PLSE
This page provides financial data for Pulse Biosciences, Inc (NASDAQ: PLSE), specifically focusing on its forward price-to-earnings ratio. The content appears to be a stub or a data-focused page from TradingView, indicating that the price-to-earnings forward value is displayed, alongside other general market and financial information for the company.
PLSE Forecast — Price Target — Prediction for 2027
This article provides a forecast for Pulse Biosciences, Inc (PLSE) stock, including analyst price targets and predictions for 2027. It details the company's recent stock performance, financial metrics like earnings and revenue, and key company information such as market capitalization and employee count. The article also addresses frequently asked questions about PLSE's stock volatility, historical prices, and upcoming earnings reports.
Price to sales forward of Pulse Biosciences, Inc – NASDAQ:PLSE
This article focuses on the "Price to sales forward" metric for Pulse Biosciences, Inc (NASDAQ: PLSE). It provides a high-level overview of the company's financial data on the TradingView platform, indicating that the market is currently closed. The content is primarily a data placeholder within a financial analysis platform.
Price to book forward of Pulse Biosciences, Inc – NASDAQ:PLSE
The article focuses on the "Price to book forward" financial metric for Pulse Biosciences, Inc. trading under the NASDAQ symbol PLSE. It appears to be a financial data presentation page from TradingView, indicating that the market for PLSE was closed with no trades at the time of viewing.
Enterprise value to revenue forward of Pulse Biosciences, Inc. – FWB:6L8
This article from TradingView briefly presents the enterprise value to revenue forward for Pulse Biosciences, Inc. (FWB:6L8). The content appears to be a stub or a data placeholder, indicating no current trading activity for the specified market. It serves primarily as a navigation point within the TradingView platform for financial data related to this company.
Enterprise value to EBIT forward of Pulse Biosciences, Inc – NASDAQ:PLSE
This article focuses on the enterprise value to EBIT forward for Pulse Biosciences, Inc. (NASDAQ: PLSE). It appears to be a financial data snippet from TradingView, indicating a specific financial metric for the company. The content includes details like the stock market, company name, and navigation within the TradingView platform.
Enterprise value to revenue forward of Pulse Biosciences, Inc – NASDAQ:PLSE
This article provides an overview of Pulse Biosciences, Inc. (NASDAQ: PLSE) with a focus on its enterprise value to revenue forward. It indicates the stock market status on Nasdaq, noting that the market is closed with no trades. The article is primarily a financial snapshot from TradingView, offering navigation to financial data and other related information about the company.
Price to book forward of Pulse Biosciences, Inc. – FWB:6L8
This page from TradingView displays financial information for Pulse Biosciences, Inc. (6L8) on the Frankfurt Stock Exchange, specifically focusing on its forward price-to-book ratio. The content also lists various TradingView products, community features, and company information.
Price to earnings forward of Pulse Biosciences, Inc. – FWB:6L8
This article provides a brief overview of Pulse Biosciences, Inc. (FWB:6L8), focusing on its forward price-to-earnings ratio. It indicates that the company is listed on the Frankfurt Stock Exchange and its market is currently closed with no trades. The content specifically highlights the "Price to earnings forward" value for the company.
Pulse Biosciences Inc (PLSE) Institutional Confidence
Pulse Biosciences Inc (PLSE) has an institutional shareholding score of 3.00, placing it 132nd out of 203 in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion recently increased by 30.37% quarter-over-quarter to 11.76%. The largest institutional shareholder is Bill Nygren | OAKMX, holding 6.89K shares, though this represents a 99.39% decrease in their holdings.
Pulse Biosciences stock hits 52-week high at $28.68
Pulse Biosciences (PLSE) stock recently reached a 52-week high of $28.68, reflecting significant investor confidence with an 82.43% increase over the past year and over 100% year-to-date. Despite this surge, InvestingPro suggests the stock may be overvalued. The company recently reported Q1 2026 EPS of -$0.27, exceeding forecasts, and announced plans to redeem common stock warrants from its July 2024 rights offering.
Pulse Biosciences, Inc. Actuals & Estimates (NASDAQ:PLSE)
This article provides an overview of Pulse Biosciences, Inc. (NASDAQ:PLSE) stock, including its current price, historical performance, and analyst forecasts. It details the company's financial actuals and estimates, such as earnings per share and revenue, and confirms that PLSE does not pay dividends.
Pulse Biosciences stock hits 52-week high at $28.68 By Investing.com
Pulse Biosciences Inc. (PLSE) stock reached a new 52-week high of $28.68, reflecting an 82.43% increase over the past year and over 100% year-to-date. This surge comes despite InvestingPro suggesting the stock may be overvalued, following positive Q1 2026 financial results, Canaccord Genuity initiating a buy rating with a $32 price target, and significant insider stock purchases. The company also announced redemption plans for common stock warrants issued in July 2024.
Pulse Biosciences, Inc. Actuals & Estimates (DUS:6L8)
This article provides financial actuals and analyst estimates for Pulse Biosciences, Inc. (DUS:6L8), including income statement, balance sheet, and cash flow data. It also covers commonly asked questions about the stock, such as its ticker, forecasts, historical prices, earnings reports, revenue, net income, dividends, employee count, and EBITDA. The stock is expected to release its next earnings report on August 12, 2026.
6L8 Forecast — Price Target — Prediction for 2027
The article provides a forecast and price target for Pulse Biosciences, Inc. (6L8) stock on the Dusseldorf Stock Exchange. Based on three analyst ratings, the stock has a price target of 26.44 EUR, with a maximum estimate of 27.59 EUR and a minimum of 25.87 EUR. The company's recent financials show an earnings surprise, with the next earnings report expected on August 12, 2026.
Companies Like Pulse Biosciences (NASDAQ:PLSE) Are In A Position To Invest In Growth
The article discusses Pulse Biosciences (NASDAQ:PLSE) and evaluates its financial position regarding growth investments. It highlights that the company has more cash than debt and positive short-term assets exceeding liabilities, suggesting a strong balance sheet for future growth.
Pulse Biosciences Inc (PLSE) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Pulse Biosciences Inc (PLSE), detailing its current price momentum score, support and resistance levels, and various technical indicators. It shows that PLSE's price momentum score is 7.45, with the stock trading between a resistance level of 28.45 and a support level of 23.52. The analysis of moving averages suggests a "Buy" signal, while other technical indicators present mixed signals.
Pulse Biosciences Inc (PLSE) Valuation: PE, PB & Fair Value Analysis
Pulse Biosciences Inc (PLSE) has a current valuation score of 9.27, ranking 26th in the Healthcare Equipment & Supplies industry. The company's P/E ratio is -23.31, reflecting a significant change from its recent high and low. Relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Pulse Biosciences (PLSE) Is Up 5.0% After Joining S&P Healthcare Equipment Index Is Sentiment Shifting?
Pulse Biosciences (PLSE) saw its stock rise by 5.0% after being added to the S&P Healthcare Equipment Select Industry Index. This inclusion enhances visibility and comes alongside a strong financial health score and increased institutional ownership. However, the company still faces challenges with ongoing losses and high operating costs despite limited revenue, with its future depending on successful commercial adoption of its nanosecond pulse field ablation platform.
Understanding Momentum Shifts in (PLSE)
This article analyzes potential momentum shifts in Pulse Biosciences Inc (PLSE), highlighting weak near-term sentiment that could precede changes in mid and long-term outlooks. It details AI-generated trading strategies for different risk profiles, including position, momentum, and risk hedging, along with multi-timeframe signal analysis indicating support and resistance levels. The report also points out an exceptional risk-reward short setup for PLSE.
Pulse Biosciences Stock - weekly review and sector comparison
This article provides a weekly review of Pulse Biosciences (PLSE) stock, focusing on its financial position and comparison within the early-stage medical device and aesthetic-technology sector. It highlights the company's focus on pulsed electric field-based medical technologies for dermatologic and aesthetic procedures and its trading characteristics as a small-cap, volatile stock. The piece also provides key financial data and market context for PLSE shares.
Pulse Biosciences Strengthens Executive Team
Pulse Biosciences has strengthened its C-Suite by appointing Liane Teplitsky as Chief Operating Officer and expanding Dr. David Kenigsberg's role to full-time Chief Medical Officer. These strategic enhancements aim to accelerate the development and commercialization of the company's nPulse Cardiac Catheter Ablation System. Teplitsky brings extensive experience in medical technology leadership, particularly in cardiovascular and electrophysiology, while Dr. Kenigsberg's increased commitment will further advance the IDE pivotal clinical study for atrial fibrillation treatment.
Pulse Biosciences Inc (PLSE) Dividends & Stock Splits: Historical Payouts and Event Timeline
The article provides a timeline of dividend and stock split events for Pulse Biosciences Inc (PLSE). It states that the company has distributed $0.00 in dividends over the past five years and lists no historical stock split data. The current stock price, market cap, and other basic financial details are also presented.
Pulse Biosciences Inc (PLSE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Pulse Biosciences Inc (PLSE). It details the company's revenue streams by business segment (Systems, Cycle units) and by geographic region (North America, Rest of World) for various fiscal periods. As of the stated update, all reported revenue figures for both segments and regions are 0.00 USD, indicating no revenue contribution in these categories for the periods shown.
Robert W. Duggan receives new PLSE stock option grants (NASDAQ: PLSE)
Robert W. Duggan, a director and 10% owner of Pulse Biosciences (NASDAQ: PLSE), has received two new stock option grants totalling 42,495 shares as part of his equity compensation. These options have an exercise price of $26.89 per share and expire on June 11, 2036. The grants will vest over a one-year period, with one vesting monthly starting July 11, 2026, and the other quarterly starting September 5, 2026, contingent on his continued service.
Pulse Biosciences (PLSE) director awarded stock options for 44,504 shares
Pulse Biosciences director Mahkam Zanganeh has been awarded two stock option grants totaling 44,504 shares (14,504 and 30,000 shares) at an exercise price of $26.89 per share, expiring on June 11, 2036. The 14,504-share option vests monthly over one year starting July 11, 2026, while the 30,000-share option vests quarterly over one year starting September 5, 2026, both subject to continued service. These compensation-related awards were reported via a Form 4 SEC filing and are not open-market transactions.
[Form 4] PULSE BIOSCIENCES, INC. Insider Trading Activity
PULSE BIOSCIENCES, INC. director Richard van den Broek reported receiving two stock option grants, which are compensation-related awards. These options allow him to buy Common Stock at an exercise price of $26.89 per share, expiring on June 11, 2036. The grants, covering 8,423 and 30,000 shares respectively, have distinct vesting schedules contingent on his continued service.
Director at Pulse Biosciences (NASDAQ: PLSE) receives new stock option grants
Pulse Biosciences director Maria Sainz was granted two stock option awards on June 11, 2026, totaling 33,793 options to purchase common stock at an exercise price of $26.89 per share. These compensation-related grants will expire on June 11, 2036. The options will vest over a one-year period, with the 3,793-share grant vesting monthly starting July 11, 2026, and the 30,000-share grant vesting quarterly starting September 5, 2026.
Pulse Bio to redeem remaining common stock warrants
Pulse Biosciences announced it will redeem all of its outstanding Series A and Series B common stock warrants. This redemption will be effective on July 15, 2024, at a redemption price of $0.0125 per warrant. Holders can exercise their warrants to purchase common stock before the redemption date.
Pulse Biosciences (PLSE) investors back all directors and Deloitte as 2026 auditor
Pulse Biosciences, Inc. shareholders approved all seven director nominees and ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, during their virtual 2026 Annual Meeting held on June 11, 2026. Each director nominee received over 33.5 million votes in favor, with significant support also shown for the reappointment of Deloitte & Touche LLP. These decisions confirm the company's board composition and external auditor for the coming year.
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
Pulse Biosciences, Inc. announced its intention to redeem the remaining common stock warrants (200% Warrants) from its July 2024 rights offering. Holders have until July 13, 2026, at 5:00 p.m. Eastern time to exercise them at $11.00 per share; otherwise, unexercised warrants will be redeemed for $0.01 per share. The company is taking this action because the specified volume weighted average price condition was met for 20 consecutive trading days preceding June 10, 2026.
Warrant redemption may add up to $2.1M for Pulse Biosciences (PLSE)
Pulse Biosciences announced the redemption of its remaining "200% Warrants" from a July 2024 rights offering, with a deadline of July 13, 2026, for holders to exercise them at $11.00 per share before they are redeemed for $0.01 per share. The company has already raised $60 million from the rights offering and $63.7 million from warrant exercises, with a potential to gain an additional $2.1 million if all outstanding warrants are exercised. This redemption was triggered because the common stock's volume-weighted average price exceeded $22.00 for 20 consecutive trading days.
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
Pulse Biosciences, Inc. (Nasdaq: PLSE) announced its intention to redeem the remaining common stock warrants ("200% Warrants") from its July 2024 rights offering. Holders have until 5:00 p.m., Eastern time, on July 13, 2026, to exercise these warrants at $11.00 per share; unexercised warrants will be redeemed for $0.01 per share. The company met the redemption condition of its volume weighted average price exceeding $22.00 for 20 consecutive trading days, receiving significant gross proceeds from warrant redemptions to date.
Pulse Biosciences to redeem remaining warrants after VWAP triggers; exercise window until July 13, 2026
Pulse Biosciences announced it will redeem its remaining 200% warrants after the Volume-Weighted Average Price (VWAP) exceeded the trigger threshold of $22.00 for 20 consecutive trading days. Warrant holders have until July 13, 2026, at 5:00 p.m. ET to exercise their warrants for $11.00 per share; unexercised warrants will be redeemed at $0.01. The company has already generated $60.0M from a rights offering and $63.7M from prior warrant redemptions.
Pulse Biosciences to redeem outstanding warrants by July 13
Pulse Biosciences announced its intent to redeem outstanding common stock warrants by July 13, 2026, after meeting the redemption criteria. The company's stock has seen significant gains, and analysts hold a bullish outlook. Recent financial results and insider stock purchases further indicate positive momentum for Pulse Biosciences.
Pulse Biosciences to redeem outstanding warrants by July 13
Pulse Biosciences announced its intention to redeem outstanding common stock warrants by July 13, 2026, offering holders the opportunity to exercise them at $11.00 per share before they are redeemed at $0.01 per share. The company's stock has seen significant year-to-date gains and analysts maintain a bullish outlook, with recent insider stock purchases further indicating confidence. This decision follows the company meeting the redemption criteria and successfully raising substantial proceeds from its rights offering and previous warrant redemptions.
Avoiding Lag: Real-Time Signals in (PLSE) Movement
This article provides a real-time analysis of Pulse Biosciences Inc (NASDAQ: PLSE) movement, highlighting a strong near-term sentiment with a long-term positive bias. It details several AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for different holding periods. The analysis also identifies key support and resistance levels for the stock.
PLSE - Pulse Biosciences Inc Stock Price and Quote
This article provides comprehensive stock information for Pulse Biosciences Inc (PLSE), including its current stock price, financial metrics, analyst ratings, and a detailed list of recent news and insider transactions. It highlights the company's focus on immuno-oncology and its Nano Pulse Stimulation (NPS) technology. The data presented covers various financial ratios, performance indicators, and recent corporate announcements regarding clinical studies, executive appointments, and financial results.
Does Pulse Biosciences’ (PLSE) Insider Buying Reinforce Canaccord’s Cardiac PFA Thesis or Raise New Questions?
Canaccord Genuity has initiated coverage on Pulse Biosciences (PLSE) with a buy rating, emphasizing its nanosecond pulsed field ablation platform for cardiac applications. This move, coupled with significant insider share purchases, suggests strong internal and external confidence in the technology's commercial potential. However, the company faces near-term challenges regarding advancing its NANOPULSE AF IDE study and addressing high losses against minimal revenue, despite promising European feasibility data.
CCORF Initiates Pulse Biosciences(PLSE.US) With Buy Rating, Announces Target Price $32
CCORF has initiated coverage on Pulse Biosciences (PLSE.US) with a Buy rating. The firm has set a target price of $32 for the company's stock. This new rating and price target suggest a positive outlook for Pulse Biosciences from CCORF.
Canaccord initiates Pulse Biosciences stock with buy on ablation tech
Canaccord Genuity initiated coverage on Pulse Biosciences Inc. (NASDAQ:PLSE) with a buy rating and a $32.00 price target, citing the company's differentiated nanosecond pulsed field ablation technology for cardiac ablation. Despite an expected lack of profitability this year, the technology is seen as a significant advancement over existing methods. Insider confidence is high, with executives recently purchasing a substantial number of shares.
PLSE Initiates Coverage On by Canaccord Genuity -- Price Target Set at $32
Canaccord Genuity has initiated coverage on Pulse Biosciences (PLSE) with a "Buy" rating and a price target of $32.00, reflecting a positive outlook on the company's Nano-Pulse Stimulation technology. While insiders have bought $13.3 million worth of shares, the company's GF Score™ of 32/100 indicates areas for improvement in profitability and growth, prompting investors to proceed with caution.
Pulse Biosciences (PLSE) Initiated with Buy Rating and $32 Targe
Canaccord Genuity has initiated coverage on Pulse Biosciences (PLSE) with a Buy rating and a $32 price target, citing the company's innovative nanosecond pulsed field ablation technology for cardiac ablation. This technology is poised to capture a significant share in the rapidly growing electrophysiology ablation market, projected to reach $3 billion. Despite a high P/S ratio and negative earnings, significant insider buying activity suggests confidence in the company's future prospects.
Canaccord initiates Pulse Biosciences stock with buy on ablation tech By Investing.com
Canaccord Genuity has initiated coverage on Pulse Biosciences (NASDAQ:PLSE) with a buy rating and a price target of $32.00, citing the company's differentiated cardiac ablation platform. Pulse Biosciences uses nanosecond pulsed field ablation, an evolution of existing technology, which Canaccord believes could lead to significant commercial adoption. Despite the positive outlook, analysts do not expect the company to be profitable this year, though recent Q1 2026 results showed an EPS beat and insider stock purchases indicate strong confidence.
PLSE Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a financial analysis of Pulse Biosciences Inc (PLSE), detailing its revenue breakdown, profitability margins, and a comparison with competitors. The company's revenue is primarily driven by Systems, accounting for 78.9% of total sales, while its gross margin stands at 7.73%, with negative operating and net margins. PLSE, with a market capitalization of $1.71B, is benchmarked against BWAY and PRCT, highlighting significant differences in gross margins.
PLSE Technical Analysis & Stock Price Forecast
Pulse Biosciences Inc (PLSE) shows a "Strong Buy" technical sentiment based on Intellectia's analysis, with 7 out of 10 indicators flashing buy signals. The stock is trading above its 60-day and 200-day moving averages, and key indicators like MACD suggest a positive outlook, while RSI indicates a neutral condition. Support is identified at $23.187 and resistance at $27.917.
PLSE - Nanosecond Pulse Field Ablation Advancements Will Transform Thyroid And Cardiac Care Over Time
Pulse Biosciences is poised to transform thyroid and cardiac care with its nanosecond pulse field ablation (PFA) technology, which is achieving early commercial success in benign thyroid nodule ablation and advancing through clinical trials for atrial fibrillation. Analysts project significant revenue growth of over 600% annually for the next three years, though profitability is not expected within that timeframe. Despite the promising outlook, the company faces risks including slow adoption, high operating expenses, and competitive pressures, with analysts setting a consensus price target of $22.0.
Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
Pulse Biosciences, Inc. announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, FL. The company's management is scheduled to present on Wednesday, June 10, at 10:00 am ET, with a live and recorded webcast available on its investor website. Pulse Biosciences is a bioelectric medicine company developing its nPulse™ technology for various medical applications, including atrial fibrillation.
